Please ensure Javascript is enabled for purposes of website accessibility
Cory Renauer

Cory Renauer

tmfang4apples

Cory is a long-term minded analyst focused on the Healthcare Sector. He genuinely enjoys cutting through the complexity to help everyday investors make better decisions.

Recent articles

scientist-with-test-tubes-getty

3 Beaten-Down Biotech Stocks: Can They Recover?

These drugmaker stocks may have been hammered down to bargain-bin prices.


scientist-with-mohawk-getty

Analyst Downgrades AstraZeneca Stock Due to Vaccine Side Effect Concerns

The odds of experiencing a fatal blood clot following inoculation with AstraZeneca's COVID-19 vaccine are less than one in a million, but that was enough to spook Argus Research.


smart-scientist-in-the-lab-getty

3 Biotech Stocks With Big Catalysts Around the Corner

Upcoming events could send these stocks screaming higher or lower.


next-generatioon-DNA-sequencing

This Unstoppable Stock Doesn't Pay a Dividend Yet, but It Could

This giant of the genomic revolution ticks nearly all the boxes dividend investors should look for.


scientist-with-pippette-getty

Is Illumina Still a Good Stock to Buy?

The company's attempts to grow through acquisition keep running into problems.

biden-2800x1560

11 Words From President Biden That Frighten Big Pharma

This is why America's largest pharmaceutical companies are nervous about the American Jobs Plan.


digital-health-test-results-getty

Forget the Vaccine Problems, AstraZeneca Stock Can Still Make You Rich

There's a lot more to AstraZeneca than poorly presented vaccine data.


should-i-buy-stock-computer-getty

Co-Diagnostics: Buy the Dip?

Analysts following this coronavirus stock have darkened their post-pandemic outlook.


2-impossibly-attractive-healthcare-professionals-getty

6 Words From Pfizer's CEO That Mean Trouble for Moderna and BioNTech

It looks like the proprietary technology that led to the first COVID-19 vaccines isn't very difficult to replicate.


scientist-lab-pipette-getty

Pfizer to Develop mRNA Vaccines Without BioNTech

The pharmaceutical heavyweight thinks it won't need any more help to whip up new mRNA-based vaccines.

Team-of-healthcare-professionals-getty

Before You Buy Zomedica Stock, Stop and Consider These 3 Things

There are a few things you should know before risking your hard-earned money on this stock.


investor-at-computer-getty

Should You Buy Cassava Sciences Stock Now?

A potential new treatment for Alzheimer's disease could be worth billions.


scientist-with-pippette-getty

3 Biotech Stocks to Avoid Right Now

Here's why these attention-grabbing stocks could be toxic to your portfolio.


telemedicine-hypertension-getty

Disruptor Alert: Amazon Care Will Soon Be Available to All U.S. Amazon Employees

The virtual-care service that launched in Seattle is going nationwide.


physician-and-patient-getty

Why Eli Lilly's Successful Alzheimer's Disease Study Was So Disappointing

Eli Lilly's latest Alzheimer's disease candidate is a terrific success and a disappointing flop at the same time.

close-up-of-scientist-looking-into-microscope-getty

3 Biotech Stocks That Have Already Rocketed Higher in 2021

Here's why these highfliers could have more fuel in the tank.


smart-scientist-in-the-lab-getty

Pfizer's Vaccine 97% Effective at Preventing COVID-19 in Real-World Study

Results from Israel suggest the Pfizer-BioNTech vaccine works even better than its phase 3 trial results indicated.


smart-person-making-decisions-getty

Does Eli Lilly Have a New Blockbuster Weight Loss Drug?

Late-stage trial results suggest a potential new diabetes drug also helps people lose a lot more weight than Novo Nordisk's semaglutide.


at-home-investor-computer-getty

Can Fulgent Genetics Stock Rebound?

New COVID-19 tests catapulted this company to fame, but investors are worried about what happens next.


making-a-deal-getty

Amgen to Buy Oncology Start-Up Five Prime Therapeutics for $1.9 Billion

The big biotech wants to bolster its late-stage pipeline with a potential new stomach cancer treatment.